Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. (ORMP) generates news at the intersection of clinical-stage drug development, oral delivery technology, and strategic healthcare investments. The company describes itself as a platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, centered on its Protein Oral Delivery (POD™) technology and a refined oral insulin program.
News about Oramed often covers clinical and strategic milestones for its oral insulin and POD™ platform, including updates on trial design, analysis of Phase 2 and Phase 3 data, and plans for U.S.-based clinical studies. Company letters to shareholders and press releases provide context on how Oramed is advancing its oral insulin program independently and how it evaluates high-responder subgroups in its clinical data.
Another major source of headlines is Oramed’s investment and partnership activity across the biomedical and medical technology landscape. Releases have detailed structured financings and royalty arrangements with Scilex Holding Company, a substantial equity investment and strategic collaboration with Alpha Tau Medical Ltd., and positions in companies such as BioXcel Therapeutics Inc. and Pelthos Therapeutics Inc. These updates often discuss repayments, warrant structures, royalty interests, and unrealized gains.
Recent news also highlights transformative corporate transactions, such as the announced transfer of Oramed’s POD™ technology to Lifeward Ltd. in exchange for a significant beneficial ownership interest and participation in a revenue-generating medical robotics business. Additional items include stock repurchase programs, cash dividend declarations, and the adoption of a Rights Agreement involving common stock purchase rights.
Investors and followers of ORMP news can use this page to review Oramed’s press releases, shareholder letters, and transaction announcements in one place, tracking developments in its oral drug delivery platform, strategic investments, and corporate actions over time.
Oramed Pharmaceuticals and Lifeward (NASDAQ: LFWD) signed binding agreements dated January 13, 2026 to transfer Oramed's POD™ oral drug delivery platform to Lifeward in exchange for Oramed receiving a 49.9% beneficial ownership interest upon satisfaction of closing conditions. Lifeward will issue two $10 million senior secured convertible notes (8% interest) with 100% warrant coverage; Oramed to invest $9M in each note. Oramed will fund and manage the upcoming clinical trial and receive 4% of net ReWalk sales for up to 10 years. Lifeward reported $26M revenue from ReWalk and AlterG in the last four quarters.
Oramed (Nasdaq: ORMP) received an $18 million payment from Scilex, representing full satisfaction of Option Agreement obligations and bringing Oramed's current returns to $118 million on its original $99.5 million Scilex investment.
Oramed retains $27 million in a note and a $12 million convertible note (convertible at Oramed's option at $36 per share), plus existing warrants and a nine-year royalty interest in Scilex products; unpaid notes carry quarterly repayments through October 2026 if not converted. The board approved a cash dividend of $0.25 per share (ex-dividend Jan 16, 2026; pay date Jan 26, 2026), an expected aggregate distribution of approximately $10.5 million funded from surplus capital.
Oramed (Nasdaq: ORMP) reported unaudited results for the nine months ended Sept 30, 2025, posting a pre-tax net income of $65.0 million versus a $6.1 million loss a year earlier.
Key drivers include the completed $100 million cash repayment from Scilex (about $27 million received in the period) and substantial unrealized fair-value gains from the company's equity holdings including Alpha Tau Medical. Total assets rose 42% year-over-year to $220.5 million. Basic EPS was $1.30 and diluted EPS $1.26. R&D expense declined to $4.4 million while G&A rose to $5.0 million for the nine-months.
Oramed Pharmaceuticals (NASDAQ:ORMP) adopted a Rights Agreement on November 17, 2025 and declared a dividend of one common stock purchase right per outstanding share.
Each Right initially permits purchase of one share at a $10.00 exercise price if Rights become exercisable, generally triggered 10 business days after any person or group acquires beneficial ownership of 15%+ of common stock or announces a tender offer for 15%+. The Board may redeem Rights at $0.012 per Right prior to an acquiring person arising. If exercisable, each Right will allow purchase of securities equal in value to 2x the exercise price; Rights held by the triggering person will be void.
The dividend is payable to holders of record on November 27, 2025, Rights expire three years after adoption, and the distribution is not taxable to stockholders.
Oramed (Nasdaq: ORMP) reported strategic progress on its oral insulin program, investment gains, and cash growth as of September 30, 2025. The company will run a 60‑patient U.S. trial focused on high‑responder subgroups that showed potential >1% HbA1c reduction. A prior joint venture with Hefei Tianhui Biotech was terminated; Oramed will continue development independently.
Oramed described a diversified investment portfolio with material realizations and paper gains (Scilex structured investment returning $95.5M to date with ~ $60M expected in next 12 months; Alpha Tau position valued at ~$64.8M; Pelthos position up ~180%). Cash and assets rose from $155.7M (Jan 2023) to ~$210M (Sep 30, 2025) (unaudited).
Oramed Pharmaceuticals has announced a $36.9 million strategic investment in Alpha Tau Medical (Nasdaq: DRTS), acquiring approximately 14.1 million ordinary shares at $2.612 per share through a registered direct offering.
The partnership includes a three-year service agreement where Oramed will provide Alpha Tau with investor outreach, strategic guidance, and capital markets expertise. The collaboration unites two therapeutic delivery pioneers, combining Oramed's oral drug delivery platform with Alpha Tau's Alpha DaRT® alpha-radiation cancer therapy technology.
As part of the deal, Oramed will appoint two directors to Alpha Tau's Board. The investment aims to support Alpha Tau's ongoing developments, including:
- US clinical trials across four indications
- Manufacturing scale-up initiatives
- Commercialization efforts
- Expansion into trials for multiple internal organs
Oramed Pharmaceuticals (NASDAQ: ORMP) has announced key developments expected for completion in 2025, centered around its new joint venture OraTech Pharmaceuticals. The venture focuses on oral insulin development with planned U.S. Phase 3 trials.
Key highlights include:
- Distribution of majority OraTech holdings to Oramed shareholders via dividend, coinciding with OraTech's planned Nasdaq listing
- Planned cash dividend of approximately $0.25 per share
- Marketing Authorization Application submitted by HTIT for oral insulin capsule in China, with OraTech expected to receive royalties
- Ongoing revenue from Scilex partnership, including $400,000 in royalties due for Q4 2024
The company maintains a strong financial position through its Scilex transaction, receiving $70 million from a $99.5 million loan agreement, with additional $53 million expected over two years. Oramed holds 12.25 million Scilex shares, increasing to 18.75 million shares, plus royalty streams from multiple products including ZTlido, ELYXYB, and GLOPERBA.
Oramed Pharmaceuticals (NASDAQ: ORMP) announced a strategic joint venture to create OraTech Pharmaceuticals, focusing on oral drug delivery technology. The new company will receive Oramed's POD™ technology and oral insulin assets, backed by a $75 million combined investment from Oramed ($15M) and Hefei Tianhui Biotech (HTIT) ($60M).
Key aspects of the deal include: Oramed shareholders will receive a majority stake in OraTech, which is expected to list on Nasdaq; HTIT will provide manufacturing capabilities and a supply agreement for oral insulin capsules; and OraTech will hold global marketing rights to the POD™ technology. A new Phase 3 trial in the U.S. with a revised protocol is planned to begin this quarter, while in China, a Marketing Authorization Application has been submitted with commercialization preparations underway by HTIT.
Oramed Pharmaceuticals (ORMP) announced a restructuring of its debt with Scilex Holding Company (SCLX). Key points:
- Oramed agreed to restructure $22.5 million of Scilex's existing Senior Secured Promissory Note
- In exchange, Oramed receives a $25 million convertible note with 5.5% interest, warrants for 3.75 million Scilex shares, and $12.5 million repayment
- Oramed and other investors will acquire rights to an 8% royalty on net sales of certain Scilex products, including ZTlido
- The restructuring extends part of the payment schedule but offers potential upside through warrants and conversion options
CEO Nadav Kidron stated the restructuring enhances the potential value of Oramed's investment in Scilex while aligning with their strategy to maximize shareholder value.
Oramed Pharmaceuticals has issued a Letter to Shareholders, highlighting several key developments. The company announced a $20 million stock repurchase program, reflecting confidence in its value. Oramed is actively engaging with the FDA on a new Phase 3 protocol for its oral insulin program, targeting specific patient subgroups. The company has received $40 million from the $102 million principal of Scilex Holding Company's Senior Secured Note, with the next $20 million installment due in September. Additionally, Oramed is finalizing a joint venture with Hefei Tianhui Biotech Co., (HTIT), which includes significant investments to support clinical and business activities. These initiatives aim to drive shareholder value and advance Oramed's oral drug delivery platforms.
FAQ
What is the current stock price of Oramed Pharmaceuticals (ORMP)?
What is the market cap of Oramed Pharmaceuticals (ORMP)?
